INAPRUBAHAN ng Food and Drug Administration ang certificate of product registration ng bivalent Covid-19 vaccine ng Pfizer para sa edad 12 pataas.
Nagsumite ng aplikasyon ang Pfizer noong Pebrero 21, 2023 para sa certificate of product registration ng Comirnaty Original/Omicron BA.4-5 COVID-19 vaccine ng Pfizer.
Limang taon ang bisa ng certificate of product registration.
“We acknowledge the collective efforts of the members of the Task Force Edward, scientific community, and researchers who have worked tirelessly to evaluate this vaccine. Their commitment to public health and the well-being of our nation has been instrumental in achieving this significant milestone,” sabi ng FDA.
Hinimok din ng FDA ang iba pang pharmaceutical industry na masumite ng aplikasyon para sa kani-kanilang COVID-19 vaccines.
